Singh JSS, Mordi IR, Vickneson K, et al. - Researchers conducted the study for analyzing the impacts of dapagliflozin in patients with heart failure (HF) and type 2 diabetes mellitus (T2DM) on left ventricular (LV) remodeling using cardiac MRI. They randomized 56 individuals with T2DM and HF with LV systolic dysfunction to dapagliflozin 10 mg daily or placebo for 1 year, on top of usual therapy. Dapagliflozin in the cohort had no impact on LV end-systolic volume or any other parameter of LV remodeling. However, while increasing hemoglobin, hematocrit, and ketone bodies, it reduced the diastolic blood pressure and loop diuretic needs. A trend toward lower weight has been seen.